NovaBridge Biosciences Secures FDA Alignment For Accelerated Approval Pathway For Givastomig In 1L HER2-, CLDN18.2+, PD-L1+ GEC Patients

Benzinga Newsdesk www.benzinga.com Positive 93.7%